日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors

开发用于NF1相关肿瘤基因替代疗法的腺相关病毒载体

Ren-Yuan Bai ,Jingyi Shi ,Jianan Liu ,Nihao Sun ,Yuqing Lu ,Xiaojun Chen ,Manzhu Xu ,Hotae Lim ,Yang Li ,Huazhen Xu ,Karis Weisgerber ,Zhihong Ren ,Christine A Pratilas ,Jaishri O Blakeley ,Melissa L Fishel ,Meritxell Carrió ,Eduard Serra ,Verena Staedtke

DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.

DLK1 可区分具有不同分子特征的 NF1 相关恶性周围神经鞘瘤亚型

Mitchell Dana K, Brewster Kylee, Makri Stavriani C, Khan Jaffar, Albright Eric A, Horvai Andrew, Mang Henry, Lu Qingbo, Dixon Shelley A H, White Emily, Saadatzadeh Mohammad Reza, Bijangi-Vishehsaraei Khadijeh, Gampala Silpa, Hickey Brooke E, Leffew Hannah, Li Xiaohong, Jiang Li, Ciesielski Marisa D, Bessler Waylan K, Collier Christopher D, Cohen-Gadol Aaron, Fishel Melissa L, Pratilas Christine A, Pollok Karen E, Angus Steven P, Rhodes Steven, Clapp Wade

Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma

艾立布林单药治疗或与伊立替康联合治疗儿童横纹肌肉瘤、非横纹肌肉瘤软组织肉瘤或尤文氏肉瘤患者的疗效、安全性和药代动力学研究

Casanova, M; Albert, C M; Bautista, F; Borinstein, S C; Bradfield, S; Bukowinski, A; Campbell-Hewson, Q; Hawkins, D S; Kim, A; Milano, G M; Marshall, L V; Pinto, N; Pratilas, C A; Rubio-San-Simón, A; Windsor, R; Majid, O; Scott, R; Jia, Y; Paoletti, C; Kontny, U

RAS pathway targeted therapy in patients with DICER1-associated sarcomas

RAS通路靶向治疗在DICER1相关肉瘤患者中的应用

Zhang, Lindy; Mallinger, Paige H R; Zhou, Serena; Makri, Stavriani C; Gross, John M; Lucas, Calixto-Hope G; Zou, Ying S; Mize, William; Olson, Damon R; Munnikhuysen, Senna R; Rawwas, Jawhar; Messinger, Yoav; Chen, Kenneth S; Schultz, Kris Ann P; Pratilas, Christine A

Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat

一名患有复发性 EZH2 突变型黑色素瘤的儿科患者接受辅助 tazemetostat 治疗后,实现了无复发生存。

Resch, Erin E; Makri, Stavriani C; Ghanem, Paola; Baraban, Ezra G; Cohen, Kenneth J; Cohen, Alan R; Lipson, Evan J; Pratilas, Christine A

Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset.

NF1相关周围神经鞘瘤的综合基因组分析:更新的生物样本库数据集

Banerjee Jineta, Lyu Yang, Makri Stavriani C, Scott Alexandra J, Zhang Lindy, Calizo Ana, Pollard Kai, Yang Kuangying, Gross John M, Lucas Calixto-Hope G, Wang Jiawan, Levin Adam S, Belzberg Allan J, Romo Carlos G, Allaway Robert J, Blakeley Jaishri O, Hirbe Angela C, Pratilas Christine A

Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors

选择性抑制BRAF和CRAF可使NF1缺陷型恶性周围神经鞘瘤对MEK抑制剂敏感。

Wang, Jiawan; Sarkar, Arnab; Garcia, Natalia; Zhang, Lindy; Calizo, Ana; Lisok, Alla; Campos, Katia; He, Funan; Punjaala, Nishanth; Marple, Teresa; Pollard, Kai; Zheng, Siyuan; Lucas, Calixto-Hope G; Cooke, Vesselina G; Pratilas, Christine A; Vaseva, Angelina V

Activity of direct KRAS(G12C) inhibitors in preclinical models of pediatric cancer.

直接 KRAS(G12C) 抑制剂在儿童癌症临床前模型中的活性。

Price Hannah E, Stauffer Stacey, Lee Hyun, Isanogle Kristine A, Wu Ying, Powell Katie, Baker Andrew, Stauffer Lucas, Perciaccante Andrew J, Jewell Connor P, Hernandez Edjay R, Aljabri Ashwaq K, Odeniyide Patience, Pratilas Christine A, Burgan William, Edmondson Elijah F, Difilippantonio Simone, Kortum Robert L, Shern Jack F, Jenkins Lisa M, Rossman Kent L, Yohe Marielle E

Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

靶向快速 TKI 诱导的 AXL 上调可克服适应性 ERK 再激活,并在 FLT3/ITD 急性髓系白血病中发挥抗白血病作用。

Seale, Tessa S; Li, Li; Bruner, J Kyle; Chou, Melody; Nguyen, Bao; Seo, Jaesung; Zhu, Ruiqi; Levis, Mark J; Pratilas, Christine A; Small, Donald

Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma.

联合抑制 SHP2 可克服 BRAF V600E 驱动的高级别胶质瘤对 1 型 BRAF 抑制剂的适应性耐药性

Ayanlaja Abiola A, Chang Michael, Lalwani Kriti, Ioannou Maria, Wang Jiawan, Jagtap Shreya, Yang Yanbo, Lucas Calixto-Hope G, Mulcahy-Levy Jean M, Gartrell Robyn D, Pratilas Christine A, Schreck Karisa C